Physician profile
Sharon Davinroy
NPI 1174048037
$585.50
in general payments reported to CMS, 2019-2025
12 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.78 · 2022: $93.10 · 2023: $208 · 2024: $103 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.62 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $125.47 | 2025 | Wegovy |
| Janssen Biotech, INC. | $109.91 | 2023 | Erleada |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $88.79 | 2022-2024 | Lifevest |
| Astellas Pharma US INC | $65.00 | 2023 | |
| Nestle Healthcare Nutrition INC. | $45.86 | 2022 | |
| Sumitomo Pharma America, INC. | $33.35 | 2023 | Gemtesa |
| Boston Scientific Corporation | $31.51 | 2024 | Lithovue |
| Astrazeneca Pharmaceuticals LP | $24.20 | 2021 | |
| Mylan Specialty L.P. | $19.53 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.93 | 2022 | |
| Merck Sharp & Dohme LLC | $13.90 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Davinroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.